by MM360 Staff | Sep 28, 2021 | Featured News, Myeloma News
Here are some interesting Myeloma journal articles and some of the most discussed on Twitter for September 2021. Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to whites: a propensity-score...
by MM360 Staff | Jun 10, 2021 | Featured News, Myeloma News
People with blood type O are significantly less likely to develop multiple myeloma, but those who do are likely to have more aggressive disease and poorer survival outcomes, a study found. The study, “Effect of the ABO blood groups on the development, clinical...
by MM360 Staff | Jun 10, 2021 | Featured News, Myeloma News
The Israeli Ministry of Health has approved Xpovio (selinexor), in combination with the corticosteroid dexamethasone, for the treatment of people with multiple myeloma who have received three or more prior therapies, and who failed to respond to at least one...
by MM360 Staff | Apr 21, 2021 | Featured, Webinars
Downloadable Slide Set In this webcast, expert faculty discuss best practices in treating patients with relapsed/refractory multiple myeloma and discuss the patient’s perspective on treatment options. Learners will also get a look ahead at emerging therapeutic...
by MM360 Staff | Apr 2, 2021 | Featured News, Myeloma News
A recent article published in JAMA Oncology1 questions whether VRd should remain as the standard of care (SOC) in newly diagnosed multiple myeloma. Careful analysis of the ENDURANCE (E1A11) phase III trial2 raises the question whether VRd continues to be the SOC for...
